ATF4 contributes to autophagy and survival in sunitinib treated brain tumor initiating cells (BTICs)

Sylvia Moeckel; Kelly LaFrance; Julia Wetsch; Corinna Seliger; Markus J. Riemenschneider; Martin Proescholdt; Peter Hau; Arabel Vollmann-Zwerenz

doi:10.18632/oncotarget.26569

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

ATF4 contributes to autophagy and survival in sunitinib treated brain tumor initiating cells (BTICs)

Sylvia Moeckel, Kelly LaFrance, Julia Wetsch, Corinna Seliger, Markus J. Riemenschneider, Martin Proescholdt, Peter Hau _ and Arabel Vollmann-Zwerenz

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2019; 10:368-382. https://doi.org/10.18632/oncotarget.26569

Metrics: PDF 1850 views | Full Text 3466 views | ?

Abstract

Sylvia Moeckel1, Kelly LaFrance1, Julia Wetsch1, Corinna Seliger1, Markus J. Riemenschneider2, Martin Proescholdt3, Peter Hau1,* and Arabel Vollmann-Zwerenz1,*

1Wilhelm Sander-NeuroOncology Unit and Department of Neurology, Regensburg University Hospital, Regensburg, Germany

2Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany

3Department of Neurosurgery, Regensburg University Hospital, Regensburg, Germany

*These authors contributed equally to this work

Correspondence to:

Peter Hau, email: [email protected]

Keywords: glioblastoma; brain tumor initiating cells; ATF4; therapy resistance; receptor-tyrosine-kinase-inhibitor

Received: August 13, 2017 Accepted: December 29, 2018 Published: January 08, 2019

ABSTRACT

Receptor tyrosine kinase (RTK) pathways are known to play an important role in tumor cell proliferation of glioblastoma (GBM). Cellular determinants of RTK-inhibitor sensitivity are important to optimize and tailor treatment strategies.

The stress response gene activating transcription factor 4 (ATF4) is involved in homeostasis and cellular protection. However, little is known about its function in GBM. We found that the ATF4/p-eIF2α pathway is activated in response to Sunitinib in primary tumor initiating progenitor cell cultures (BTICs). Furthermore, lysosome entrapment of RTK-inhibitors (RTK-Is) leads to accumulation of autophagosomes. In case of Sunitinib treated cells, autophagy is additionally increased by ATF4 mediated upregulation of autophagy genes. Inhibition of ATF4 by small interfering RNA (siRNA) reduced autophagy and cell proliferation after Sunitinib treatment in a subset of BTIC cultures.

Overall, this study suggests a pro-survival role of the ATF4/p-eIF2α pathway in a cell type and treatment specific manner.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26569

Publication Alerts

Research Papers:

ATF4 contributes to autophagy and survival in sunitinib treated brain tumor initiating cells (BTICs)

Abstract